Background
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced a rapid pandemic evolution, with infected individuals of all ages in almost all the countries around the world. In Sicily, the first wave of COVID-19 showed a low epidemic impact in our paediatric population, while the second and the third waves had a higher impact on clinical presentation of COVID-19 in children and a significantly higher severe outcome in patients with MIS-C, frequently showing a life-threatening progression.
However, the lower incidence of paediatric cases of severe COVID-19 was and is yet associated with the emergence of the multisystem inflammatory syndrome affecting children in relation to COVID-19 called “multisystem inflammatory syndrome in children” (MIS-C). MIS-C is characterized by hyperinflammation, secondary to cytokine storm and shows some similarities with severe COVID-19 in adult patients [1, 2].
Anzeige
Most children affected were RT-PCR negative for SARS-CoV-2 virus, but were antibody positive, indicating past infection. The pathogenesis of the clinical syndrome was postulated to be a late inflammatory response following SARS-CoV-2 infection.
The main clinical symptoms are persistent fever, conjunctivitis, oral mucosal changes, vomiting, diarrhoea, abdominal pain, respiratory symptoms, myocardial dysfunction, capillary leak and cardiogenic shock. Patients with MIS-C show a significant overlap of symptoms with hyper-inflammatory diseases such as Kawasaki disease (KD), KD-related shock syndrome or Toxic Shock Syndrome (TSS), associated with hypotension, platelet consumption and increased risk of CAL, and Macrophage Activation Syndrome (MAS) [3]. This overlap may occur despite the different aetiology of these conditions, joint by the activation and the dysregulation of pathways implicated in innate immune response, inflammation, and tissue damage induction. Inflammatory markers show significant increase in MIS-C, but none is specific and sensitive for the diagnosis. Treatment approaches chosen in other hyper-inflammatory syndromes have been used to control the hyper-inflammation in MIS-C. However, the long-term implications of cardiac sequelae in MIS-C are unknown but need a strict follow-up, as in KD [4].
At the follow-up, KD patients who developed CAL, show that aneurisms tend to regress, mostly medium-sized and small-sized aneurysms. The regression may be secondary to myointimal cells proliferation and/or to thrombus organization followed by recanalization. However, it is not possible to exclude long-term sequelae even in the non-complicated patients. Hence, it is strategic a long-term follow-up in KD patients with both persistent and regressed aneurysms with different timing and mode [5]. Children with KD-TSS have a higher incidence of CAL, than children without TSS. For these patients, the cardiologic follow-up is essential, also after the resolution of the acute critical phase.
The overlap of clinical features of MIS-C and KD induced researchers to consider the two conditions as the same disease, with the documented trigger of SARS-CoV-2 in MIS-C, and the suspicion of superantigens as the starting step in KD [6]. However, with the support of following studies, MIS-C was differentiated from KD on the bases of epidemiological, clinical, biochemical, and topographic records.
Anzeige
In fact, many children show respiratory symptoms or have an acute abdominal presentation. Intravenous immunoglobulin (IVIG) is recommended as first line therapy, as in KD. Recent evidence suggests IVIG resistance in some cases of MIS-C, thereby questioning the benefit of steroids and immunomodulators such as interleukin (IL) IL-1 or IL-6 blocking agents. Furthermore, the efficacy of anakinra in patients with a severe outcome of MIS-C, has a common pathogenetic underground with the results in non-responders or at high-risk patients with KD [7‐9].
Methods
We describe a cohort of 22 Sicilian children (11 M; 11 F; age: 1.4–14 years), with MIS-C, and a documented recent or actual infection by SARS-CoV-2, hospitalized from April 2020 to July 2021. The follow-up was performed for 10 months after discharge. Some cases showed shock and/or MAS secondary to a cytokine storm, fulfilling the CDC and WHO case definitions of MIS-C [1], including any of the following:
o
positive SARS-CoV-2 RT-PCR
p
positive serology
q
positive antigen test
r
contact with an individual with COVID-19.
Demographic and clinical data, laboratory, echocardiographic and imaging findings, treatment strategy and outcome were collected.
Common presenting symptoms included:
-
-fever, an essential criterion in the definition of MIS-C;
-
-abdominal pain and/or vomiting and/or diarrhoea, mucocutaneous rash, conjunctivitis, latero-cervical lymphadenitis, cheilitis and/or pharyngeal hyperaemia, hands and feet oedema.
Nasopharyngeal swab for SARS-CoV-2 was performed in all the patients and in their caregivers, and serological IgM and IgG-type antibodies against SARS-CoV-2 were dosed in all the children. Anamnestic records about positive parents’ swab were collected.
For this study, ethical review and approval was not required, because the data were retrospectively gathered.
Statistics
Patients were classified by gender and age; symptoms, clinical signs, drugs employed, treatment interval, were correlated with organ damage, ultrasound findings and normal or altered haematological parameters. Correlation between the analysed parameters collected were performed, using Chi-square test. All variables were tested for normal distribution, using the Anderson–Darling normality test. All ordinal data were expressed as numbers and percentages. Statistical analysis was done by “MiniTAB release 13.1 Statistical Software”.
Results
Symptoms started 1–8 days before the hospitalization. The following diagnostic criteria were detected in the patients included in the study:
-
-fever (was present in 100% of the cases)
-
- cheilitis and/or pharyngeal hyperaemia (86%)
-
- latero-cervical lymphadenitis (82%)
-
- skin rash (73%)
-
- conjunctivitis (64%)
-
- abdominal pain and/or vomiting and/or diarrhoea (64%)
-
- hands and feet oedema (18%) (Table 1).
Table 1
Clinical signs and symptoms of the patients
Patients (age in years) | fever (days) | Rash | Conjunctivitis | lymphadenitis | cheilitis and/or pharyngeal hyperaemia | hands and feet oedema | abdominal pain and/or vomiting and/or diarrhoea | Arrhythmia | Pleuritis | Ascitis | Mesenteric adenitis | Pericarditis | Valvular insuff | CAL | MAS | Shock |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 (12.7) M | 5 | + | - | + | + / + | - | -/-/- | + | - | + | + | - | + (M) | - | ||
2 (6) F | 6 | - | + | + | -/ + | - | ± /- | + | - | - | - | - | + (M) | - | ||
3 (3) F | 3 | + | + | + | + / + | - | -/-/- | - | - | - | + | - | - | - | ||
4 (2.8) F | 3 | + | - | + | + / + | - | -/-/- | - | - | + | - | - | - | - | MAS | |
5 (11) M | 11.9 | + | + | + | + / + | - |
+ / + / +
| - | - | - | - | - | - | + | - | - |
6 (11) M | 6 | + | + | + | + / + | - | + / + / + | + | - | + |
+
| - | + (T) | + | ||
7 (9) M | 5 | + | + | + | -/- | - | -/-/- | - | - | + | + | + | + (M) | + | ||
8 (9.4) M | 7 | - | + | - | + / + | - | + / + / + | + | + | - | + | - | + (M) | - | ||
9 (5.4) F | 6 | + | + | + | + / + | - | + / + / + | - | - | + | + | + | + (M) | - | MAS | |
10 (0.4) F | 10 | + | - | + | + / + | + | + / ± | - | + | - | - | - | - | - | ||
11 (1) M | 7 | + | + | - | + / + | - | -/-/- | - | - | - | - | - | - | - | ||
12 (11.7) F | 6 | + | - | + | -/- | - | + / + / + | + | - | + | + | - | + (M) | - | ||
13 (2) M | 6 | + | + | + | -/ + | - | -/ ± | - | - | - | - | - | + (A; M) | - | ||
14 (1.1) F | 9 | + | + | + | + / + | + | -/-/- | + | - | - | - | - | - | - | ||
15 (14) F | 4 | + | - | + | -/ + | - | -/ + / + | - | - | - | - | - | + (A; M) | + | ||
16 (11) M | 12 | - | - | + | -/ + | - | -/-/ + | - | - | - | + | + (M) | - | |||
17 (3) F | 5 | + | + | - | + / + | - | -/ ± | + | - | - | + | - | - | - | ||
18 (10.4) F | 7 | + | + | + | + / + | - | + / + / + | - | - | - | - | + | + (M; T) | - | ||
19 (7.6) M | 8 | - | - | + | -/ + | + | ± /- | - | + | + | - | - | - | - | MAS | Shock |
20 (3.2) M | 5 | + | + | + | + / + | + | -/-/- | - | - | - | - | - | - | - | ||
21 (14) F | 6 | - | + | - | -/- | - | -/ + / + | + | + | - | - | + | - | - | MAS | Shock |
22 (1.5) M | 4 | - | - | + | + / + | - | -/-/- | - | - | - | - | - | - | - |
Anzeige
Nasopharyngeal swab for SARS-CoV-2 was positive in 15/22 patients, who showed positive serological IgG, negative or grey zone IgM-type antibodies. 5 patients with negative swab had a history of recent infection and positive IgG-type antibodies; 2 patients had parents with positive swab, with no positive serological test, however fulfilling the CDC and WHO case definitions of multisystem inflammatory syndrome in children [1].
Infections other than SARS-CoV-2 were excluded in all the patients, by haemoculture and sept fast.
At the admission, a significant increase of C-reactive protein (CRP) and hyponatraemia was found in 100% of cases. AST, ALT, gamma-GT were above the range in 59% of the children. Increased pancreatic amylase and lipase levels were found in 14%, a lymphocyte count ≤ 1000 was documented in 36% of the patients enrolled.
Pro-BNP levels were increased (> 320 pg/ml) in 50% and troponin levels were increased (> 14 ng/ml) in 18% of cases.
Anzeige
D-Dimer was increased in all the patients, with a range of 0.56–13.36 mg/L (n.v. < 0.5); ferritin was increased (with levels > 365 ng/ml) in 11/22 (50%) of the patients.
IL-6 levels were evaluated in 14/22 patients and 13/14 showed a significant increase of IL-6 levels (30.2–285 pg/ml).
Furthermore, a mild kidney involvement was documented in 36% of the patients, with low-grade proteinuria in 8 and microhaematuria in 3 (Table 2).
Table 2
Laboratory parameters of the patients
Patients | Nasopharingeal Swab | IgM/IgG anti-SARS-CoV-2 | Hb g/dl | WBC/µL | Neutrophils/lymphocytes/ µL | Platelets/µL | CRP (n.v. < 0.5 mg/dl) | Procalcitonin (µg/l) | Protein/albumin (g/dl) | Creatinine (mg/dl) | Na /K/ Cl (mmol/l) | AST /ALT (UI/l) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | + | IgG + | 13.9 | 8860 | 5883/1940 | 209,000 | 10.89 | 0,4 | 7.3/4.5 | 0.66 | 134/3.95/101 | 32/33 |
2 | + | IgG + /I gM + | 10.3 | 19,490 | 16,118/2163 | 157,000 | 23.78 | 7,39 | 6.2/3.5 | 0.43 | 132/4.21/100 | 22/9 |
3 | + | IgG + /I gM + | 10.3 | 9670 | 6720/2592 | 221,000 | 8.65 | 1,22 | 6.2/3.3 | 0.29 | 134/3.75/99 | 27/14 |
4 | + | 12.6 | 1910 | 850/1000 | 162,000 | 9.13 | 10.1 | 6.7/3.9 | 0.3 | 132/4.94/92 | 72/166 | |
5 | - | IgG + /I gM + | 24,430 | 21,498/977 | 407,000 | 16.4 | 6.9/2.9 | 0.76 | 133/3.4/98 | 34/36 | ||
6 | + | IgG + /I gM + | 12.3 | 6230 | 5794/318 | 121,000 | 11.03 | 6.86 | 6,6/3.5 | 0.61 | 130/4.12/95 | 37/39 |
7 | - | IgG + /I gM- | 10.1 | 1129 | 857/151 | 138,000 | 10.58 | 17.27 | 6.2/2.8 | 0.45 | 128/3.79/99 | 51/30 |
8 | + | IgG + /I gM + | 12 | 4680 | 3800/580 | 70,000 | 12.03 | 5,91 | 6.8/3.7 | 0.53 | 127/3.65/90 | 24/57 |
9 | + | IgG + /I gM ± | 10 | 2090 | 1269/650 | 59,000 | 4.56 | 1.28 | 5.1/3 | 0.38 | 135/3.86/104 | 26/19 |
10 | + | 11.5 | 17,030 | 1450/13980 | 492,000 | 2.5 | 6.3/4.4 | 0.26 | 133/5.31/102 | 31/35 | ||
11 | + | IgG + /I gM + | 11.7 | 9650 | 3420/5170 | 224,000 | 5.76 | 5/3.3 | 0.53 | 132/4.6/99 | 60/22 | |
12 | - | IgG + /I gM + | 14.7 | 8210 | 5120/2580 | 180,000 | 26.65 | 7.8/3.8 | 0.54 | 133/4.8/96 | 39/73 | |
13 | + | IgG + /I gM- | 11.1 | 20,820 | 14,803/2311 | 293,000 | 3.56 | 3.37 | 7.2/3.7 | 0.4 | 132/4.4/100 | 105/53 |
14 | - | IgG -/IgM - | 12.5 | 5300 | 779/4182 | 169,000 | 1.88 | 0.57 | 6,1/3.7 | 0.28 | 132/4.01/102.4 | 63/64 |
15 | + | IgG + /I gM + | 12.3 | 10,340 | 2833/5201 | 309,000 | 0.29 | < 0.05 | 7.9/4.3 | 0.77 | 133/2.25/99.3 | 18/21 |
16 | + | IgG + /I gM- | 11.2 | 16,860 | 14,769/1332 | 332,100 | 25.99 | 3.69 | 6.1/3.5 | 0.46 | 124/3.43/87 | 42/52 |
17 | - | IgG + /I gM- | 10.8 | 10,370 | 7715/1742 | 237,000 | 9.03 | 5.9/3.6 | 0.4 | 134/4.1/103 | 57/12 | |
18 | - | IgG + /I gM- | 11.3 | 7470 | 6499/829 | 220,300 | 42.24 | 5.7/3.5 | 0.5 | 133/3.7/98 | 19/17 | |
19 | + | 10.8 | 15,780 | 13,381/1594 | 210,000 | 27.2 | 0.31 | 6.9/3.5 | 0.53 | 124/4.22/86 | 273/254 | |
20 | + | 10.6 | 7010 | 3870/2208 | 396,000 | 9.43 | 1.35 | 8.8/3.7 | 0.3 | 134/3.7/96 | 16/7 | |
21 | + | 12.9 | 5710 | 3909/622 | 132,000 | 21.16 | 5.2 | 7/4.1 | 1.29 | 131/3.03/103 | 156/80 | |
22 | + | 9 | 29,610 | 19,661/7284 | 394,000 | 17.29 | 0.66 | 8,1/4.4 | 0.34 | 133/5.57/97 | 25/9 |
Patients | CPK /LDH (UI/l) | Gamma GT (UI/l) | pancreatic amylase/lipase (U/L) | Troponine (ng/l) | PRO-BNP (pg/ml) | D- Dimer | Fibrinogen (mg/dl) | Ferritin (ng/ml) | Triglyceride (mg/dl) | IL-6 (pg/ml) | haematuria | Proteinuria |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 46/174 | 14 | 16/13 | 66.6 | 3908 | 1.49 | 560 | 386.8 | 279 | 16.7 | - | - |
2 | 61/348 | 11 | 5.8 | 2.112 | 645 | 187 | 285 | + | + | |||
3 | 8/382 | 12 | 33/39 | 3.39 | 1565 | 584 | 118.3 | 219 | 57.1 | - | - | |
4 | 64/541 | 96 | 11/18 | 4.27 | 2193 | 1.79 | 525 | 364.4 | 745 | 65.6 | - | + |
5 | 34/331 | 46 | 98/38 | 3 | 2.13 | 151 | 1300 | 366 | - | - | ||
6 | 50/332 | 14 | 14/13 | 3 | 6.84 | 528 | 338.5 | 162 | - | - | ||
7 | 53/413 | 16 | 12/12.9 | 4.9 | 1559 | 5.5 | 550.6 | 659.1 | 77 | 233 | - | - |
8 | 334 | 17 | 8.58 | 13.36 | 527 | 1013 | 194 | 244 | - | + | ||
9 | 327 | 50 | 63/51 | 5.5 | 323 | 1.85 | 466 | 812 | 202 | 209 | - | + |
10 | 113/305 | 10 | 23/34 | 0.56 | 159 | - | - | |||||
11 | 25/21.5 | 6 | 310 | 2357 | 280 | - | - | |||||
12 | 21/282 | 34 | 269/278.7 | 8.64 | 2704 | 4.37 | 271 | 934 | 364 | 298 | - | - |
13 | 111/369 | 7 | 5.3 | 587 | 5.2 | 4497 | 124.1 | 649 | - | + | ||
14 | 502 | 21 | 23/34 | 6.01 | 129 | 2.73 | 368 | 135.6 | 117 | 30.2 | - | - |
15 | 136 | 17 | 11/18 | 3.3 | 67 | 1.139 | 342 | 10 | 2.82 | - | - | |
16 | 14/357 | 96 | 409 | 726 | 1.91 | 696 | 180 | - | + | |||
17 | 95/301 | 10 | 69/51.9 | 7.35 | 930 | 1.12 | 147.6 | 117 | 76.1 | - | - | |
18 | 65/268 | 19 | 38/33.2 | 29.7 | 3204 | 2.73 | 614.3 | 204 | + | + | ||
19 | 454/24 | 307 | 136 | 27.3 | 2.798 | 1445 | 212 | - | - | |||
20 | 46/164 | 7 | 3 | - | - | |||||||
21 | 12,542/445 | 51 | 32 | 12.5 | 2.86 | 815.7 | + | + | ||||
22 | 31/413 | 10 | 6/11 | < 3 | 702 | 2.272 | 104.4 | 70 | - | - |
Patients were divided in two groups: group A (with cardiac involvement: pericarditis, valvular damage, CAL) and group B (without cardiac involvement) (Table 3).
Table 3
M ± DS and significant p-value (in red) of haematochemical parameters, dividing the patients in two groups: group A (with cardiac involvement: pericarditis, valvular damage, CAL) and group B (without cardiac involvement)
Parameters | Value (M ± DS) Group A | Value (M ± DS) Group B |
p-value |
|---|---|---|---|
Hbg/dl | 11.8 ± 1.5 | 11 ± 1.2 | 0.538 |
WBC/µL | 10,486 ± 7486 | 11,814 ± 8175 | 0.698 |
Neu/µL | 7934 ± 6566 | 6427 ± 6409 | 0.599 |
Lymph/µL | 1512 ± 1368 | 4417 ± 4113 |
0.027
|
Plt/µL | 202,100 ± 106,057 | 278,333 ± 117,782 | 0.129 |
CRP (n.v. < 0.5 mg/dl) | 16.09 ± 11.61 | 7.1 ± 10.9 | 0.194 |
Procalcitonin (µg/l) | 5.14 ± 4.99 | 2.37 ± 3.81 | 0.176 |
Protein (g/dl) | 6.68 ± 0.81 | 6.67 ± 1.16 | 0.981 |
Albumin (g/dl) | 3.6 ± 0.51 | 3.76 ± 0.41 | 0.444 |
Creatinine (mg/dl) | 0.6 ± 0.24 | 0.36 ± 0.11 |
0.011
|
Na (mmol/l) | 131 ± 3 | 132 ± 3 | 0.538 |
AST (UI/l) | 47 ± 40 | 69 ± 79 | 0.381 |
ALT (UI/l) | 40 ± 22 | 65 ± 87 | 0.331 |
Gamma-GT (UI/l) | 55 ± 87 | 59 ± 104 | 0.913 |
Pancreatic amylase (U/l) | 61 ± 83 | 39 ± 44 | 0.462 |
IL-6 (pg/ml) | 230.35 ± 178.34 | 101.80 ± 101.06 | 0.066 |
LDH (UI/l) | 315 ± 90 | 383 ± 123 | 0.155 |
Ferritin (ng/ml) | 601 ± 418 | 667 ± 887 | 0.816 |
Fibrinogen (mg/dl) | 804 ± 1248 | 530 ± 270 | 0.527 |
D-dimer (mg/l) | 3.72 ± 3.37 | 2.47 ± 1.76 | 0.322 |
Anzeige
Proteinuria and microhaematuria were more frequent in patients of group A (7/13) than in of group B (1/9) (p-value: 0.0019). Furthermore, in group A lymphocyte count was lower (p-value: 0.027) and creatinine was higher (p-value: 0.0113).
Patients of group A had higher CRP levels (16.09 ± 11.61) than in group B (7.1 ± 10.9) and procalcitonin concentrations (5.14 ± 4.99) than group B (2.37 ± 3.81), even not reaching the statistical significance.
The cardiac involvement was documented by echocardiogram in 59% of children (pericardial effusion in 5; Mitral or Tricuspid insufficiency in 8; Mitral and Aortic insufficiency in 2; Mitral and Tricuspid insufficiency in 1; 4 with coronary artery lesions (CAL)). The Z score value was 3 in 1 patient; 3 patients showed a Z score < 3, with persistent brightness of the coronary wall. 4/5 (80%) of patients with pericarditis showed Mitral valve insufficiency as well. All the patients showed normal left ventricular ejection fraction. The ejection fraction of patients with cardiac involvement was > 60%. The 2 patients with shock did not show reduced cardiac contractility.
De-novo arrhythmia was documented in 8/22 children (36%): among those, tachycardia followed by persistent bradycardia was documented in 5 (23%), lasting for 8–10 days after the resolution of the acute phase of MIS-C. It was not correlated with increased levels of troponin and pro-BNP. Among those children who developed bradycardia, 2 showed alterations of the repolarization phase. Further 3 children showed alterations of the repolarization terminal phase or of the QRS, not known before. One patient showed a pre-existing Brugada pattern, revealed by fever with arrythmia.
Pleural effusion, ascitic effusion and mesenteric adenitis were found in 18%, 27% and 36% of the patients, respectively.
18% of patients dramatically and rapidly evolved in a MAS-like form, fulfilling the classification criteria for the diagnosis of MAS (ACR/EULAR 2016). High doses of steroids were promptly started and associated with IVIG, obtaining a significant improvement of the clinical course.
In all the patients, treatment was started within 72 h after the admission, with IVIG (2 g/Kg/dose), methylprednisolone (2 mg/Kg/day in 73% of patients; 30 mg/Kg/day for 3 days, followed by 2 mg/Kg/day in 27% of patients for the severe and acute progression of the MIS-C), acetylsalicylic acid (ASA) (3–5 mg/Kg/day). Two patients were treated with enoxaparin. Two patients with shock, were additionally treated with vasoactive drugs, albumin, diuretics. All the patients were treated with methylprednisolone at 1–2 mg/Kg/day until the normalization of inflammatory markers (CRP, ferritin, IL-6), troponin, D-Dimer, AST, ALT, gamma-GT, pancreatic amylase, lipase, lymphocyte count.
Hence, a gradual and slow tapering of methylprednisolone was performed, with the end of the therapy in 2–3 weeks. Treatment with low dose of ASA was maintained for 6–8 weeks, in patients with the resolution of CAL. The child with persistent CAL is still treated with ASA.
In this case series, no patients needed treatment with anakinra, indicated in patients who are refractory to IVIG and steroids, due to its efficacy in treating systemic inflammatory diseases.
All the patients were included in a follow-up, to investigate on clinical outcome and resolution of organ involvement. The follow-up was performed for a median time of 10 months and included medical examination, blood samples, ECG and echocardiogram, abdominal US.
Haematological parameters normalized in all the patients. The patients with increased pancreatic amylase showed the restore of pancreatic enzymes in 2 weeks. Proteinuria and/or haematuria resolved in 5 ± 2 days after the start of IVIG and steroids. Nobody showed a relapse of signs of kidney damage during the follow-up.
IL-6 levels showed a prompt normalization after steroids and IVIG treatment. At the contrary, the increase of pro-BNP levels persisted for 7–10 days after IVG and steroids treatment.
In all the patients, during the follow-up, we did not observe an inflammation rebound, with maintained normal levels of CRP, ESR, IL-6, ferritin, LDH, fibrinogen, D-Dimer. Troponin and pro-BNP levels, after the normalization, persisted in the normal range for all the period of the follow-up, as the other biochemical markers, also in patients with persistent valvular insufficiency or CAL.
Cardiac damage evolved into the complete resolution of lesions in most of the patients. The resolution was observed and documented by echocardiogram after 7–14 days since IVIG and steroids treatment was started. The time occurred between the diagnosis and the resolution of cardiac involvement was not correlated with biochemical parameters. One patient with pre-existing Mitral valve insufficiency had a persisting defect; in 1 patient, Mitral and Tricuspid insufficiency persisted over all the time of follow-up; 1 patient with pre-existing aortic insufficiency, worsened during the acute phase of MIS-C, showed the reduction of aortic insufficiency during the follow-up, while Mitral insufficiency reached the complete resolution. In 3 patients the Mitral insufficiency reduced but did not resolve during the follow-up.
In conclusion, 18% of patients with acquired valvular insufficiency persisted with the valvular impairment during the follow-up.
CAL resolved in 2 patients, within 2 weeks since IVIG and methylprednisolone treatment was started, persisted in 1, which is still treated with ASA at 5 mg/Kg/day.
The treatment strategy, the timing and the dosage of methylprednisolone did not differ between patients with and those without resolution of valvular or coronary lesions.
Discussion
MIS-C is considered as a post-infectious inflammatory response following SARS-CoV-2 infection. It shows a different clinical presentation, linked to cytokine storm occurring weeks later the contact with the virus. The patients with MIS-C usually do not have anamnestic records of co-morbidities and have a common clinical presentation, associated with gastrointestinal symptoms, as abdominal pain, vomiting and/or diarrhoea. The cardiac involvement can vary, between cases with CAL, cases with valvulitis, pericarditis and/or shock.
The clinical presentation is widely different from severe acute COVID-19 in paediatric patients, who are younger, can manifest comorbidities, upper and low airway symptoms and respiratory dysfunction [10].
These patients show a wide range of presenting symptoms and signs. They show the evidence of inflammation with increased values of erythrocyte sedimentation rate (ESR), CRP, IL-6, ferritin, D-dimer, pro-BNP, troponin, transaminase, pancreatic amylase and albumin. A multi-organ involvement was described in most of cases, in some cases with an overlap with acute SARS-CoV-2 infection, requiring a multi-specialistic approach [11]. Furthermore, the mild kidney involvement was reported as an organ involvement in children with MIS-C [12]. In our patients it resolved in a few days after the immunomodulatory treatment.
Resolving systemic inflammation, pro-BNP usually improves within a few days, troponin may persist high for longer until the regenerative repair of apoptotic cells is completed. Generally, pro-BNP and troponin levels in MIS-C are higher than in KD and reflect the extent of vasculopathy and cardiomyocytes damage [13]. Persistence of increased levels of pro-BNP, in patients with a normalization of inflammatory parameters, suggests a mechanism of myocardial oedema, persisting besides the intensive care approach, able however to limit effects on cardiac function and normalize inflammatory parameters [14].
An open question is about the long-term cardiac complications in children with MIS-C. Children treated with immunomodulators showed a favourable outcome in most cases, with recovery of pericardial effusion, CAL, valvular insufficiency, left ventricular contractility [13‐15]. We still not know if the cardiac lesions observed in the acute phase of the disease are persistent or transient, and if they are the beginning of a persistent cardiomyopathy.
During the 10 months follow-up we documented a persistence of valvular impairment in 18% of patients in with valvular inflammation was documented during the acute phase of MIS-C.
The international literature documented that the early evidence of pericarditis in KD is significantly correlated with CAL onset [16]. Thereby, pericarditis must be considered an alarm and precocious sign of CAL and/or valvular damage in children with KD. In our patients with MIS-C, 80% of patients with pericarditis showed contemporary mitral valve insufficiency. This discrepancy between the two conditions, commonly considered as “twin diseases” for the clinical presentation, the laboratory findings and the treatment choices, highlights intrinsic differences between KD and MIS-C. In fact, MIS-C typically shows an acute and severe cardiac involvement in most critical cases. Conversely, CAL can develop also during the follow-up in KD. Echocardiogram in the first week of illness is typically normal and does not exclude KD diagnosis. In fact, KD vasculitis is caused by diffuse neutrophil infiltration with necrotizing features of small arteries, which might potentially lead to vessel dilatation generally occurring during the subacute phase [17].
In our patients, cardiac valve involvement persisted only in 18% of children, CAL persisted only in 33% of children with coronary involvement, however without the evolution into aneurisms. In our Sicilian children with KD, we documented a higher incidence of persisting CAL [16], suggesting that cardiac involvement in MIS-C manifests at the beginning and seems more severe in the acute phase of the disease, while tends to resolve in a higher percentage of children. These data need to be confirmed in a longer period of follow-up. However, the persistence of valvular heart disease proves that post-inflammatory fibrosis can maintain the endothelial damage in heart tissues. The treatment strategy and timing did not differ between patients with resolution and those with persisting injuries.
It is a key matter to investigate the factors associated with the resolution of CAL, valvular damage, and myocardial dysfunction in children with MIS-C. The drugs employed and the timing of therapeutic approaches can contribute to resolve the cardiac lesions. The cornerstone for an effective treatment of MIS-C could be the early use of a good immunomodulatory therapy. An open question is if there is a “golden hour” for starting the treatment [18].
The preferred treatment strategy was more aggressive at the diagnosis of MIS-C, to block the cytokine cascade. Most of our patients, in fact, received a first-line treatment with IVIG and steroids. This approach could explain the favourable prognosis, the rapid restoring of cardiac function also in patients with MAS or shock, and the good outcome during the 10 months follow-up in all the patients.
All the patients did not show persistent organ damage nor inflammatory rebound during the follow-up, sustaining the benefits of the treatment strategy adopted in these cases.
Treatment with methylprednisolone at 30 mg/kg/day, was chosen in 27% of our patients, for the severe and acute presentation of the MIS-C. We strictly followed the patients and obtained a good response to treatment. For this reason, anakinra was not indicated, also for the favourable course of the disease.
Conclusions
Further studies on long-term outcomes of those patients are needed to understand the disease and to perform definitive guidelines for the management of MIS-C.
More studies are necessary to evaluate if persistent or transient cardiac complications are associated with long-term adverse cardiovascular events in adulthood, and if genetic imprinting can influence the outcome.
Acknowledgements
Not applicable
Declarations
Ethics approval and consent to participate
All methods were performed in accordance with the ethical standards as laid down in the Declaration of Helsinki and its later amendments or comparable ethical standards. The approval by ethics committee was not applicable because the data retrospectively collected were all the items needed by the follow-up of these patients and by a good clinical practice for children with MIS-C. No experimental drugs were employed, and no blood samples, other than all required in consideration of the standards of care, were done. Written informed consent was obtained from a parent and/or legal guardian. The parents wrote the informed consent on ethics approval and consent. The written consent is in the documents in the hospital “G. Di Cristina”, ARNAS Palermo, Italy. The consent was collected in the clinical documents. The approval by the ethics committee was not required for the type of work; it was a collection and analysis of laboratory, clinical, instrumental evaluations required for a good clinical practice.
Consent for publication
Not applicable. Consent was required to the patients’ parents.
Competing interests
All the authors declare no conflicts of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.